In June 2024, Sarepta Therapeutics voluntarily paused dosing in its clinical trials of Elevidys—a gene therapy for Duchenne muscular dystrophy—after a patient died during the trial. While details remain limited, the FDA was promptly notified, and Sarepta has acknowledged the “serious safety event” that triggered the halt.
We use cookies to improve your browsing experience on our website. By closing this banner or interacting with our site, you acknowledge and agree to our privacy policy.
